u/Firefly5647
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
globenewswire.comu/Firefly5647 — 1 day ago
▲ 6 r/PharmAla_MDMA
SPV FORMATION, SHAREHOLDER AND LICENSE AGREEMENT between PharmAla Biotech Holdings Inc. and Aluvaris Inc.
cdn-ceo-ca.s3.amazonaws.comu/Firefly5647 — 4 days ago
▲ 7 r/PharmAla_MDMA
“Pyrrolidines like APA-01 have great potential in treating neurodegenerative disorders, according to a recent publication. Earlier this week, PharmAla launched Restora Neuroscience, a special purpose vehicle designed specifically to bring APA-01 to first-in-human testing.”
reddit.comu/Firefly5647 — 5 days ago
How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation
pharmadevicenews.comu/Firefly5647 — 8 days ago
Genevieve Jurvetson (@gjurvetson) on X
“When Resilient submits its updated data to the FDA, I hope the FDA prioritizes the review. It is the only program with completed Phase 3 trials for PTSD and is positioned to begin treating patients immediately following approval.”
u/Firefly5647 — 9 days ago
▲ 6 r/PharmAla_MDMA
Psychedelic Alpha (@Psyched_Alpha) on X - Rachel Yehuda, Trauma and psychedelic therapy researcher
x.comu/Firefly5647 — 29 days ago
▲ 14 r/PharmAla_MDMA
Interview with Nick Kadysh, CEO PharmAla Biotech, on a historic executive order to fast-track MDMA and psilocybin therapy for veterans
townhall.comu/Firefly5647 — 29 days ago
u/Firefly5647 — 2 months ago
u/Firefly5647 — 1 month ago